InstalabTotal + Free PSA
Should you take a Total + Free PSA test?
This test is most useful if any of these apply to you.
3 Biomarkers Included
About Total + Free PSA
A single prostate number on a blood test can spike your anxiety without giving you a clear answer. Prostate-specific antigen (PSA) rises with cancer, but it also rises with aging, infection, and the benign enlargement that affects most men after 50. Roughly three out of four men who get a prostate biopsy based on an elevated total PSA alone turn out not to have cancer.
This panel adds two pieces of information that total PSA cannot provide on its own: the amount of PSA circulating in its unbound form (free PSA) and the proportion of free PSA relative to the total (free PSA ratio). Together, these three values help you and your physician decide whether an elevated reading calls for further investigation or watchful monitoring.
What This Panel Reveals
PSA is a protein made almost exclusively by the prostate. It enters the bloodstream in two forms. Most of it binds to carrier proteins. A smaller fraction circulates freely. Cancer cells tend to release more of the bound form, while benign prostate tissue releases more of the free form. That difference is the biological basis for this panel.
Total PSA gives you the overall quantity of the protein in your blood. Values below 4.0 ng/mL (nanograms per milliliter) have traditionally been considered normal, though cancer can exist at any level. In a large U.S. prevention trial involving over 2,900 men who underwent biopsy despite having PSA levels at or below 4.0 ng/mL, 15.2% were found to have prostate cancer. The risk rose in a graded fashion: men with PSA between 3.1 and 4.0 ng/mL had a 26.9% cancer detection rate.
Free PSA and the free PSA ratio become most useful when total PSA falls in the so-called diagnostic gray zone, between 4.0 and 10.0 ng/mL. In this range, roughly 25% of men will have cancer on biopsy and 75% will not. Total PSA alone cannot sort one group from the other.
Why the Ratio Changes Everything
The free PSA ratio (free PSA divided by total PSA, expressed as a percentage) is where this panel earns its value. In a multicenter study of 773 men with total PSA between 4.0 and 10.0 ng/mL, using a free PSA cutoff of 25% detected 95% of cancers while avoiding 20% of unnecessary biopsies. Men with a free PSA ratio below 10% had a cancer probability above 50%, while those with a ratio above 25% had a probability below 8%.
Additional studies in the same PSA range have confirmed the pattern: the lower the ratio, the higher the likelihood of cancer. Men in the lowest free PSA ratio categories consistently show a substantially higher risk of cancer compared to men in the highest categories.
How to Read Your Results Together
The three values in this panel form a decision tree. Start with total PSA to establish the overall level. Then use the free PSA ratio to interpret what that level likely means.
| Total PSA | Free PSA Ratio | What This Pattern Suggests |
|---|---|---|
| Below 4.0 ng/mL | Any | Low immediate risk. Consider baseline tracking, especially if you have family history or are of African descent. |
| 4.0 to 10.0 ng/mL | Above 25% | Likely benign. Prostate enlargement or inflammation is the more common explanation. Retest in 3 to 6 months. |
| 4.0 to 10.0 ng/mL | 10% to 25% | Intermediate risk. Discussion with a urologist about imaging or biopsy is appropriate. |
| 4.0 to 10.0 ng/mL | Below 10% | Higher cancer probability. Urologic evaluation and likely biopsy are recommended. |
When total PSA exceeds 10.0 ng/mL, cancer probability is high enough (roughly 50% or greater) that the free PSA ratio adds less value. At that level, direct urologic referral is the standard recommendation regardless of the ratio.
When Results Can Be Misleading
Several common situations can push total PSA up without any cancer being present. A urinary tract infection, recent ejaculation (within 48 hours), vigorous cycling, or a digital rectal exam (in which a doctor feels the prostate through the rectum) shortly before the blood draw can all cause temporary elevations. Benign prostatic hyperplasia (BPH), the noncancerous prostate enlargement that affects roughly half of men by age 60, is the most common reason for a modestly elevated PSA.
Medications also matter. 5-alpha-reductase inhibitors (finasteride, dutasteride), prescribed for BPH or hair loss, roughly cut PSA levels in half. If you take one of these drugs, your measured PSA should be doubled to estimate the true value. Failing to account for this can mask a rising trend.
The free PSA ratio itself can be affected by how the blood sample is handled. Free PSA degrades faster than bound PSA at room temperature. If the sample sits too long before processing, the measured free PSA drops and the ratio appears artificially low, which could trigger unnecessary concern.
Tracking Over Time
A single PSA result is a snapshot. Serial measurements over time create a trend line that is more informative than any isolated number. The rate of change in PSA over time (called PSA velocity) adds another dimension. A rise of more than 0.75 ng/mL per year has been associated with increased cancer risk in some studies, though its independent predictive value when added to total and free PSA remains debated.
Tracking the free PSA ratio alongside total PSA is where serial testing becomes especially powerful. A total PSA that rises from 5.0 to 7.0 over two years is concerning. But if the free PSA ratio remains stable above 25%, the rise is more likely driven by benign growth. If the ratio drops from 22% to 12% over the same period, the shift toward bound PSA suggests a different process may be at work.
Beyond This Panel
These three values give you and your doctor a framework for next steps. The interpretation table above maps each result pattern to a recommended course of action. For men in the gray zone with a low free PSA ratio, additional tools such as the Prostate Health Index (PHI), 4Kscore, and a specialized prostate MRI scan (magnetic resonance imaging) can further refine the probability of clinically significant cancer before committing to a biopsy.